Anuh Pharma Share Price

Anuh Pharma Limited is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The Company is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. The company is part of the SK Group with the key products including antibiotics, erythromycin salts, chloramphenicol and other chemicals. It is well positioned to service its existing and potential markets through its manufacturing operations at Tarapur in Maharashtra.The Company was incorporated on February 19, 1960. The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra. All the facilities are built and operated according to cGMP. They also received plant approvals from several MNCs.The business headquarters of the firm is located in the commercial capital of India, Mumbai. The company is a recognized export house and exports their products to Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore and several other countries.During the year 200607, the company commissioned the new plant with all latest modern techniques and facilities. Thus, the production capacity of Antibiotics increased from 400,000 Kg to 600,000 Kg.During the year 200809, the company completed the ongoing expansion of their plant, thus they increased the installed capacity by 150 MT per annum. In September 2008, they expanded unit started commercial production.In January 2010, the company received approval for their product Erythromycin E.P. from European Directorate for the Quality of Medicines HealthCare (EDQM). This approval paves the way for the company to sell Erythromycin E.P. in European counties for their own consumption.In April 2010, the company received approval for their product Pyrazinamide from European Directorate for the Quality of Medicines HealthCare (EDQM). This approval paves the way for the company to sell Pyrazinamide in European countries for their own consumption.In June 2010, the company received approval for their product Clobetasol Propionate from European Directorate for the Quality Medicines Healthcare. This approval paves the way for the company to sell Clobetasol Propionate in European counties for their own consumption.The erection of a new plant for manufacture of drug intermediates, was completed during the year 201011 and it got commissioned towards end of February, 2011. In 2012, it received WHO PQ for Pyrazinamide acquired RD assets in Mahape, Navi Mumbai got DSIR approval. In 2014, it got approval from COFEPRIS Mexico for Erythromycin Estolate, Erythromycin Stearate, Erythromycin Ethyl Succinate. In 2015, it received approval of WHO PQ for Sulfadoxine.In March 2019, the Company opened new expansion with an additional capacity of 900 MTPA for 20 different products. It commissioned the new expansion project by starting commercial production in December, 2019.It received CEP for Ambroxol Hydrochloride from EDQM in 2022. In FY 202324, Company enhanced production capacity from 1,500 MTPA to 1,800 MTPA at Boisar site.In FY 2025, Company made strong progress with the launch of six new products, adding 40 new export customers and partnerships, and further strengthening its regulatory foundation. The Company steadily expanded its infrastructure by operating a total of 9 API blocks and 2 intermediate blocks, bringing the total installed capacity to 2,400 metric tons per annum in FY 2025.